Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.

被引：0

作者：

Chiara Garassino, Marina

Gadgeel, Shirish M.

Rodriguez-Abreu, Delvys

Felip, Enriqueta

Esteban, Emilio

Speranza, Giovanna

Hochmair, Maximilian

Francis Powell, Steven

Garon, Edward B.

Hui, Rina

Nogami, Naoyuki

Cristescu, Razvan

Morrissey, Michael

Loboda, Andrey

Kobie, Julie

Ayers, Mark

Piperdi, Bilal

Catherine Pietanza, Maria

Snyder, Alexandra

Reck, Martin

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[2] Karmanos Canc Inst, Detroit, MI USA

[3] Univ Michigan, Ann Arbor, MI 48109 USA

[4] Univ Las Palmas Gran Canaria, Complejo Hosp Univ Insular Maternoinfantil Gran C, Las Palmas Gran Canaria, Spain

[5] Hosp Univ Vall dHebron, Barcelona, Spain

[6] Hosp Univ Cent Asturias, Oviedo, Spain

[7] Univ Sherbrooke, Ctr Integre Cancerol Monteregie, Greenfield Pk, PQ, Canada

[8] Otto Wagner Hosp, Vienna, Austria

[9] Sanford Hlth, Sioux Falls, SD USA

[10] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[11] Westmead Hosp, Sydney, NSW, Australia

[12] Univ Sydney, Sydney, NSW, Australia

[13] Shikoku Canc Ctr, Matsuyama, Ehime, Japan

[14] Merck & Co Inc, Kenilworth, NJ USA

[15] German Ctr Lung Res, Airway Res Ctr North, LungenClin, Grosshansdorf, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9521

引用

页数：2

共 50 条

[31] Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study
Horinouchi, H.
Nogami, N.
Saka, H.
Nishio, M.
Tokito, T.
Takahashi, T.
Kasahara, K.
Hattori, Y.
Ichihara, E.
Adachi, N.
Sawada, T.
Shimamoto, T.
Noguchi, K.
Pietanza, M. C.
Kurata, T.
ANNALS OF ONCOLOGY, 2019, 30
[32] KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).
Schmid, Peter
Cortes, Javier
Bergh, Jonas C. S.
Pusztai, Lajos
Denkert, Carsten
Verma, Sunil
McArthur, Heather L.
Kummel, Sherko
Ding, Yu
Karantza, Vassiliki
Dang, Thao
Dent, Rebecca Alexandra
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[33] 24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.
Gentzler, Ryan D.
Langer, Corey J.
Borghaei, Hossein
Gadgeel, Shirish M.
Papadimitrakopoulou, Vassiliki
Patnaik, Amita
Powell, Steven Francis
Martins, Renato G.
Stevenson, James
Jalal, Shadia Ibrahim
Panwalkar, Amit W.
Yang, James Chih-Hsin
Gubens, Matthew A.
Sequist, Lecia V.
Awad, Mark M.
Fiore, Joseph
Saraf, Sanatan
Keller, Steven M.
Gandhi, Leena
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[34] Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).
Ozguroglu, Mustafa
Alva, Ajjai Shivaram
Csoszi, Tibor
Matsubara, Nobuaki
Geczi, Lajos
Cheng, Susanna Y.
Fradet, Yves
Oudard, Stephane
Vulsteke, Christof
Morales-Barrera, Rafael
Flechon, Aude
Gunduz, Seyda
Loriot, Yohann
Rodriguez-Vida, Alejo
Mamtani, Ronac
Yu, Evan Y.
Nam, Kijoeng
Imai, Kentaro
Moreno, Blanca Homet
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[35] Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.
Jabbour, Salma K.
Lee, Ki Hyeong
Frost, Nicolaj
Kowalski, Dariusz
Breder, Valeriy Vladimirovich
Pollock, Theodore
Reguart, Noemi
Houghton, Baerin
Quantin, Xavier
Keller, Steven M.
Liu, Hong
Piperdi, Bilal
Reck, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[36] First-Line Pembrolizumab plus Chemotherapy Versus Placebo plus Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
Monk, Bradley J.
Colombo, Nicoletta
Tewari, Krishnansu S.
Dubot, Coraline
Caceres, M. Valeria
Hasegawa, Kosei
Shapira-Frommer, Ronnie
Salman, Pamela
Yanez, Eduardo
Gumus, Mahmut
de Mendoza, Mivael Olivera Hurtado
Samouelian, Vanessa
Castonguay, Vincent
Arkhipov, Alexander
Tekin, Cumhur
Li, Kan
Keefe, Stephen M.
Lorusso, Domenica
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36) : 5505 - +
[37] Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
Vamsidhar Velcheti
Xiaohan Hu
Bilal Piperdi
Thomas Burke
Scientific Reports, 11
[38] Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
Velcheti, Vamsidhar
Hu, Xiaohan
Piperdi, Bilal
Burke, Thomas
SCIENTIFIC REPORTS, 2021, 11 (01)
[39] Real-world outcomes using pembrolizumab plus pemetrexed-platinum in 1st line metastatic NSCLC compared to results reported from KEYNOTE-189: a multicentre experience
Ravindra, Saranya
Murphy, Ravindhi
Ferjani, Isra
Clark, James
Ahmed, Dalia
Power, Danielle
Hatcher, Olivia
Mohammed, Waleed
Newsom-Davis, Tom
Evans, Joanne
LUNG CANCER, 2021, 156 : S46 - S46
[40] Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189 (vol 155, pg 53, 2021)
Garon, Edward B.
Aerts, Joachim
Kim, Jong Seok
Muehlenbein, Catherine E.
Peterson, Patrick
Rizzo, Maria Teresa
Gadgeel, Shirish M.
LUNG CANCER, 2023, 183

← 1 2 3 4 5 →